Protagenic Therapeutics granted Japan patent for modified stilbenoid epilepsy drug candidates

Protagenic Therapeutics, Inc.new

Japanese Patent Office granted Patent JP 7714571B on July 18, 2025, covering modified stilbenoid compounds.
Patent runs until March 31, 2041, providing exclusivity for treating epilepsy and seizures.
Builds on previously granted UK patent GB2609814 for same program.
Japanese pharma market worth >$85B; global epilepsy drug market expected to reach $18.7B by 2034.
Company expects to expand patent protection to other territories.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.